Platyphylline (Pyrrolizidine Alkaloid · Anticholinergic · Regulatory Reference)
| Compound | Platyphylline (Platifilin; 13-Hydroxysarracine N-oxide precursor) |
| Class | Alkaloid — Pyrrolizidine (Saturated/retronecine-type macrocyclic ester) |
| CAS | 480-30-8 |
| Molecular formula | C₁₈H₂₇NO₅ |
| Primary sources | Senecio platyphyllus, Senecio jacobaea (ragwort), Petasites spp. |
| Plant part | Aerial parts |
| Claim strength | Moderate (pharmaceutical); Emerging (toxicology) |
| Key applications | Anticholinergic pharmaceutical (historical Soviet use); spasmolytic; informational-only |
| Buy from Herbuno | Informational reference — see HerbIQ Compound Index → |
Name origin: Platyphylline is named after Senecio platyphyllus (platy = flat/broad, phyllus = leaf), the primary Soviet-era pharmaceutical source. Unlike most pyrrolizidine alkaloids studied primarily for their toxicity, platyphylline occupies the unusual position of having been developed as a pharmaceutical anticholinergic agent in the Soviet Union — suggesting that not all PAs are equivalent in their safety profiles. Traditional and pharmaceutical context: Platyphylline was used as a pharmaceutical anticholinergic in Soviet medicine under the brand name Platifilin — administered by injection for treatment of smooth muscle spasm, peptic ulcer, and as pre-anaesthetic medication. This represents one of the very few cases of a PA being developed as a therapeutic agent. The pharmaceutical application reflects platyphylline's distinct pharmacology relative to hepatotoxic PAs: it is a saturated PA (lacking the critical 1,2-double bond in the pyrrolizidine ring required for CYP-mediated toxic pyrrole generation), which substantially reduces its hepatotoxic risk. Research trajectory: Modern research has clarified that platyphylline's reduced hepatotoxicity results from its saturated pyrrolizidine ring — it cannot form the dehydropyrrolizidine pyrrole intermediates responsible for liver damage in unsaturated PAs. This structural distinction is pharmacologically and toxicologically significant. Safety context: While substantially less hepatotoxic than unsaturated PAs, platyphylline is pharmacologically active as an anticholinergic and carries drug-level risks (tachycardia, urinary retention, constipation, CNS effects) at anticholinergic doses. It is not a supplement ingredient.
Pharmacological Profile of Platyphylline
Anticholinergic (muscarinic antagonist) activity: Platyphylline competitively inhibits muscarinic acetylcholine receptors (M1–M3), producing smooth muscle relaxation, decreased secretions, and tachycardia at pharmacological doses. Its potency as an anticholinergic is lower than atropine (approximately 1/10 the potency), but its duration of action is longer. Soviet clinical use at 1–2 mg subcutaneously for gastrointestinal spasm and peptic ulcer represents the primary human pharmacological data. Claim strength: Moderate (pharmaceutical).
Reduced hepatotoxicity vs. unsaturated PAs: Platyphylline's saturated 1,2-bond in the pyrrolizidine ring means it cannot undergo CYP3A4-mediated dehydrogenation to the reactive pyrrolic species responsible for hepatotoxicity in retrorsine, lasiocarpine, and senecionine. This is a critical structural distinction: not all pyrrolizidine alkaloids are equally hepatotoxic, and saturated PAs have substantially lower liver injury risk. Claim strength: Moderate (comparative toxicology).
Spasmolytic activity: Beyond muscarinic antagonism, platyphylline has direct myotropic (papaverine-like) smooth muscle relaxant activity, contributing to its antispasmodic profile in gastrointestinal applications. This dual mechanism — anticholinergic + direct myotropic — parallels the pharmacology of hyoscine (scopolamine), though platyphylline has lower CNS penetration. Claim strength: Moderate.
PA regulatory context: Despite its reduced hepatotoxicity, platyphylline is classified by regulatory agencies within the general PA class for monitoring purposes. EFSA's PA monitoring framework does not distinguish saturated from unsaturated PAs in maximum level calculations — a conservative approach that applies the same limits regardless of structural type. Claim strength: High (regulatory).
This compound is documented for research and formulator education purposes. For commercially available botanical ingredients, explore the HerbIQ Compound Index →
Regulatory and Formulator Context
Platyphylline's pharmaceutical history as Platifilin in the Soviet Union is relevant to understanding the full pharmacological range of pyrrolizidine alkaloids. It demonstrates that the PA structural class encompasses compounds with genuine therapeutic utility (platyphylline, retronecanol esters) alongside potent hepatotoxins (lasiocarpine, senecionine).
Platyphylline-containing plants (Senecio platyphyllus) are not commercial botanical ingredients. The compound is documented here for regulatory reference — formulators working with any Senecio family plants or Petasites preparations should be aware that PA screening is required regardless of species, given the heterogeneity of the PA class within this genus.
Petasites hybridus (butterbur) is a commercial botanical ingredient with evidence for migraine prophylaxis (Petadolex® standardised to petasins). Butterbur preparations must be certified PA-free by quantitative LC-MS/MS analysis — the manufacturing process specifically removes PAs (including any platyphylline from Petasites) to meet regulatory requirements. PA-free butterbur certification (typically <0.1 μg/day total PAs) is an industry-standard quality requirement for commercial butterbur extract products.
The anticholinergic pharmacology of platyphylline has no application in dietary supplements. Anticholinergic drugs are subject to prescription-only requirements in most markets due to their cardiovascular and CNS risk profile. Informational documentation only.
Frequently Asked Questions — Platyphylline
Why is platyphylline less hepatotoxic than most pyrrolizidine alkaloids?
The hepatotoxicity of pyrrolizidine alkaloids depends critically on the presence of a 1,2-double bond in the pyrrolizidine ring — this allows CYP3A4 to generate the reactive dehydropyrrolizidinium pyrrole intermediates that alkylate hepatocyte DNA. Platyphylline has a saturated pyrrolizidine ring (no 1,2-double bond), so it cannot undergo this metabolic activation. The absence of the reactive pyrrole pathway substantially reduces its hepatotoxic and genotoxic potential relative to unsaturated PAs like lasiocarpine, retrorsine, or senecionine.
Was platyphylline genuinely used as a pharmaceutical drug?
Yes. Platifilin (platyphylline hydrotartrate) was an official Soviet pharmaceutical preparation used from the 1950s onward for smooth muscle spasm, peptic ulcer pre-treatment, and pre-anaesthetic sedation via subcutaneous injection. It appears in Soviet-era pharmacopoeias and pharmacological references as an anticholinergic with lower toxicity than atropine. Its use declined with the availability of more selective and better-characterised anticholinergic drugs. This pharmaceutical history is unusual for a PA compound and reflects the importance of structural specificity within the PA class.
Does Petasites (butterbur) contain platyphylline?
Petasites hybridus contains PAs including senkirkine and platyphylline-related compounds. Commercial butterbur extracts certified as PA-free (Petadolex®, for example) use a manufacturing process that removes these PAs to undetectable levels. The PA-free certification is the critical quality requirement for safe butterbur supplement use — uncertified or unprocessed Petasites preparations should not be used due to PA hepatotoxicity risk from unsaturated congeners.
How should formulators treat saturated PAs differently from unsaturated PAs in quality specifications?
Practically, formulators should apply the same EFSA monitoring framework (28-PA panel, LC-MS/MS) regardless of saturation status — both because current EU maximum levels apply to total PAs without structural discrimination, and because most PA contamination scenarios involve mixtures of saturated and unsaturated PAs from the same plant sources. The distinction between saturated and unsaturated PAs is important for understanding mechanistic toxicology and interpreting risk, but does not justify separate or relaxed analytical testing requirements.
Related compounds: Retrorsine, Lasiocarpine, Lycopsamine, Senkirkine
Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.
← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery